Clinical Trials · NCT01642914

Safety and Efficacy of Linaclotide in Patients With Chronic Constipation and Prominent Abdominal Bloating

CompletedPhase 3Linaclotide (Approved)
Phase
Phase 3
Recruitment status
Completed
Sponsor
Forest Laboratories
Enrollment
487
Start date
Aug 2012
Locations
151 sites, United States, Canada
Primary endpoint
9/12 Week Complete Spontaneous Bowel Movement (CSBM) 3+1 Responder
View Linaclotide compound reference